Morgan Stanley’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-657,354
| Closed | -$24.8M | – | 7987 |
|
|
2021
Q1 | $24.8M | Buy |
657,354
+615,789
| +1,482% | +$15.4M | ﹤0.01% | 1720 |
|
|
2020
Q4 | $707K | Buy |
41,565
+26,876
| +183% | +$337K | ﹤0.01% | 4862 |
|
|
2020
Q3 | $69K | Sell |
14,689
-8,048
| -35% | -$40.9K | ﹤0.01% | 5592 |
|
|
2020
Q2 | $139K | Sell |
22,737
-37,437
| -62% | -$154K | ﹤0.01% | 5243 |
|
|
2020
Q1 | $136K | Buy |
60,174
+8,387
| +16% | +$35.6K | ﹤0.01% | 5054 |
|
|
2019
Q4 | $237K | Sell |
51,787
-109,393
| -68% | -$433K | ﹤0.01% | 5346 |
|
|
2019
Q3 | $624K | Sell |
161,180
-97,137
| -38% | -$533K | ﹤0.01% | 4582 |
|
|
2019
Q2 | $1.56M | Buy |
258,317
+237,933
| +1,167% | +$2.27M | ﹤0.01% | 3967 |
|
|
2019
Q1 | $273K | Sell |
20,384
-56,723
| -74% | -$647K | ﹤0.01% | 4897 |
|
|
2018
Q4 | $718K | Buy |
77,107
+10,838
| +16% | +$129K | ﹤0.01% | 4538 |
|
|
2018
Q3 | $923K | Sell |
66,269
-33,681
| -34% | -$501K | ﹤0.01% | 4598 |
|
|
2018
Q2 | $1.58M | Buy |
99,950
+5,245
| +6% | +$91.5K | ﹤0.01% | 4285 |
|
|
2018
Q1 | $1.63M | Sell |
94,705
-256,961
| -73% | -$5.01M | ﹤0.01% | 4182 |
|
|
2017
Q4 | $7.71M | Buy |
351,666
+298,399
| +560% | +$9.6M | ﹤0.01% | 2655 |
|
|
2017
Q3 | $2.18M | Sell |
53,267
-83,509
| -61% | -$2.62M | ﹤0.01% | 3801 |
|
|
2017
Q2 | $4.12M | Buy |
136,776
+15,092
| +12% | +$471K | ﹤0.01% | 3055 |
|
|
2017
Q1 | $4.4M | Buy |
121,684
+13,750
| +13% | +$606K | ﹤0.01% | 2981 |
|
|
2016
Q4 | $5.41M | Buy |
107,934
+75,424
| +232% | +$3.96M | ﹤0.01% | 2906 |
|
|
2016
Q3 | $1.71M | Buy |
32,510
+22,568
| +227% | +$1.08M | ﹤0.01% | 3624 |
|
|
2016
Q2 | $411K | Sell |
9,942
-43,024
| -81% | -$1.87M | ﹤0.01% | 4544 |
|
|
2016
Q1 | $2.15M | Buy |
52,966
+42,363
| +400% | +$1.46M | ﹤0.01% | 3292 |
|
|
2015
Q4 | $440K | Sell |
10,603
-745
| -7% | -$25K | ﹤0.01% | 4630 |
|
|
2015
Q3 | $175K | Sell |
11,348
-8,199
| -42% | -$176K | ﹤0.01% | 5149 |
|
|
2015
Q2 | $485K | Sell |
19,547
-57,318
| -75% | -$1.28M | ﹤0.01% | 4735 |
|
|
2015
Q1 | $1.76M | Buy |
76,865
+70,051
| +1,028% | +$1.77M | ﹤0.01% | 3695 |
|
|
2014
Q4 | $184K | Sell |
6,814
-16,107
| -70% | -$277K | ﹤0.01% | 5287 |
|
|
2014
Q3 | $269K | Buy |
22,921
+4,934
| +27% | +$62.3K | ﹤0.01% | 4976 |
|
|
2014
Q2 | $280K | Buy |
17,987
+12,625
| +235% | +$181K | ﹤0.01% | 4975 |
|
|
2014
Q1 | $106K | Buy |
5,362
+4,901
| +1,063% | +$83.2K | ﹤0.01% | 5428 |
|
|
2013
Q4 | $8K | Buy |
+461
| New | +$5.73K | ﹤0.01% | 6086 |
|
Morgan Stanley's FPRX Position: Q2 2021 in Review
Morgan Stanley sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 657,354 shares — an estimated $24.8M sold.
Morgan Stanley first reported a position in FPRX in Q4 2013 and held it in 30 quarters. The position peaked at $24.8M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Morgan Stanley reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Morgan Stanley sold 657,354 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $24.8M.
- Morgan Stanley first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 30 quarters.
- Morgan Stanley's Five Prime Therapeutics, Inc. position peaked at $24.8M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Morgan Stanley's 13F filing for Q2 2021, filed 16 Aug 2021.